{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:56:26Z","timestamp":1790672186140,"version":"4.1.0"},"reference-count":45,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Pleural mesothelioma (PM) comprises three main subtypes: epithelioid, biphasic and sarcomatoid, which have different impacts on prognosis and treatment definition. However, PM subtyping can be complex given the inter- and intra-tumour morphological heterogeneity. We aim to use immunohistochemistry (IHC) to evaluate five markers (Mesothelin, Claudin-15, Complement Factor B, Plasminogen Activator Inhibitor 1 and p21-activated Kinase 4), whose encoding genes have been previously reported as deregulated among PM subtypes. Immunohistochemical expressions were determined in a case series of 73 PMs, and cut-offs for the epithelioid and non-epithelioid subtypes were selected. Further validation was performed on an independent cohort (30 PMs). For biphasic PM, the percentage of the epithelioid component was assessed, and IHC evaluation was also performed on the individual components separately. Mesothelin and Claudin-15 showed good sensitivity (79% and 84%) and specificity (84% and 73%) for the epithelioid subtype. CFB and PAK4 had inferior performance, with higher sensitivity (89% and 84%) but lower specificity (64% and 36%). In the biphasic group, all markers showed different expression when comparing epithelioid with sarcomatoid areas. Mesothelin, Claudin-15 and CFB can be useful in subtype discrimination. PAI1 and PAK4 can improve component distinction in biphasic PM.<\/jats:p>","DOI":"10.3390\/diagnostics13182945","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T10:00:23Z","timestamp":1694685623000},"page":"2945","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["New Immunohistochemical Markers for Pleural Mesothelioma Subtyping"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8397-6479","authenticated-orcid":false,"given":"Ios\u00e8","family":"Di Stefano","sequence":"first","affiliation":[{"name":"Surgical, Medical, Molecular, and Critical Care Pathology Department, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Al\u00ec","sequence":"additional","affiliation":[{"name":"Surgical, Medical, Molecular, and Critical Care Pathology Department, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0212-8249","authenticated-orcid":false,"given":"Anello Marcello","family":"Poma","sequence":"additional","affiliation":[{"name":"Surgical, Medical, Molecular, and Critical Care Pathology Department, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Bruno","sequence":"additional","affiliation":[{"name":"Unit of Pathological Anatomy, University Hospital of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Proietti","sequence":"additional","affiliation":[{"name":"Unit of Pathological Anatomy, University Hospital of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Niccoli","sequence":"additional","affiliation":[{"name":"Unit of Pathological Anatomy, University Hospital of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3240-9313","authenticated-orcid":false,"given":"Carmelina Cristina","family":"Zirafa","sequence":"additional","affiliation":[{"name":"Multispecialty Centre for Surgery, Minimally Invasive and Robotic Thoracic Surgery, University Hospital of Pisa, 56100 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1773-8269","authenticated-orcid":false,"given":"Franca","family":"Melfi","sequence":"additional","affiliation":[{"name":"Multispecialty Centre for Surgery, Minimally Invasive and Robotic Thoracic Surgery, University Hospital of Pisa, 56100 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9291-5619","authenticated-orcid":false,"given":"Maria Giovanna","family":"Mastromarino","sequence":"additional","affiliation":[{"name":"Unit of Thoracic Surgery, University Hospital of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9909-6820","authenticated-orcid":false,"given":"Marco","family":"Lucchi","sequence":"additional","affiliation":[{"name":"Unit of Thoracic Surgery, University Hospital of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Fontanini","sequence":"additional","affiliation":[{"name":"Surgical, Medical, Molecular, and Critical Care Pathology Department, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"ref_1","unstructured":"WHO Classification of Tumours Editorial Board (2021). Thoracic Tumours, International Agency for Research on Cancer (IARC). [5th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Brims, F. (2021). Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma. Cancers, 13.","DOI":"10.3390\/cancers13164194"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"893","DOI":"10.5858\/arpa.2018-0020-RA","article-title":"Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: Ten Years of Clinical Experience in Relation to International Guidelines","volume":"142","author":"Hjerpe","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1016\/j.cllc.2018.08.007","article-title":"Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival","volume":"19","author":"Verma","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1200\/JCO.2017.73.8401","article-title":"Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis","volume":"35","author":"Nelson","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.thorsurg.2020.08.007","article-title":"Pathology of Malignant Pleural Mesothelioma","volume":"30","author":"Hung","year":"2020","journal-title":"Thorac. Surg. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1002\/cncr.32416","article-title":"Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma","volume":"125","author":"Chirieac","year":"2019","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/modpathol.2009.180","article-title":"Sarcomatoid mesothelioma: A clinical-pathologic correlation of 326 cases","volume":"23","author":"Klebe","year":"2010","journal-title":"Mod. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","article-title":"Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions","volume":"48","author":"Alcala","year":"2019","journal-title":"eBioMedicine"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bruno, R., Poma, A.M., Ali, G., Distefano, C., Proietti, A., Chella, A., Lucchi, M., Melfi, F., Franco, R., and Fontanini, G. (2022). Gene Expression Analysis of Biphasic Pleural Mesothelioma: New Potential Diagnostic and Prognostic Markers. Diagnostics, 12.","DOI":"10.3390\/diagnostics12030674"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100260","DOI":"10.1016\/j.ctarc.2020.100260","article-title":"Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland","volume":"25","author":"Vizcaya","year":"2020","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"26744","DOI":"10.18632\/oncotarget.15814","article-title":"Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma","volume":"8","author":"Inaguma","year":"2017","journal-title":"Oncotarget"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"12554","DOI":"10.1038\/s41598-021-91464-0","article-title":"CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma","volume":"11","author":"Watanabe","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ejca.2010.09.044","article-title":"Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: An exploratory analysis","volume":"47","author":"Sidi","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"825","DOI":"10.6004\/jnccn.2016.0087","article-title":"NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016","volume":"14","author":"Ettinger","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4149\/neo_2014_031","article-title":"Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study","volume":"61","author":"Capkova","year":"2014","journal-title":"Neoplasma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2020.08.005","article-title":"The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas","volume":"105","author":"Prabhakaran","year":"2020","journal-title":"Hum. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1245\/s10434-015-4374-x","article-title":"Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma","volume":"22","author":"Kadota","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"42053","DOI":"10.18632\/oncotarget.5974","article-title":"MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: Correlation with pathological and clinical data","volume":"6","author":"Pasello","year":"2015","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/his.14916","article-title":"High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma","volume":"83","author":"Chu","year":"2023","journal-title":"Histopathology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1746-1596-5-47","article-title":"Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry","volume":"5","author":"Sandeck","year":"2010","journal-title":"Diagn. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","article-title":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): A randomised, open-label phase 2 trial","volume":"23","author":"Kindler","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/modpathol.2012.172","article-title":"Mesothelioma with signet-ring cell features: Report of 23 cases","volume":"26","author":"Ordonez","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hager, T., Borchert, S., Wessolly, M., Mathilakathu, A., Mairinger, E., Kollmeier, J., Mairinger, T., Hegedus, B., Greimelmaier, K., and Wohlschlaeger, J. (2023). One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076356"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Weidemann, S., Gagelmann, P., Gorbokon, N., Lennartz, M., Menz, A., Luebke, A.M., Kluth, M., Hube-Magg, C., Blessin, N.C., and Fraune, C. (2021). Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. Biomedicines, 9.","DOI":"10.3390\/biomedicines9040397"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.humpath.2010.03.002","article-title":"Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter","volume":"41","author":"Tan","year":"2010","journal-title":"Hum. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7163","DOI":"10.1111\/jcmm.15167","article-title":"Twist1 accelerates tumour vasculogenic mimicry by inhibiting Claudin15 expression in triple-negative breast cancer","volume":"24","author":"Zhang","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"9476","DOI":"10.18632\/oncotarget.3269","article-title":"Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis","volume":"6","author":"Tabaries","year":"2015","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3892\/ol.2021.12739","article-title":"Low CFB expression is independently associated with poor overall and disease-free survival in patients with lung adenocarcinoma","volume":"21","author":"He","year":"2021","journal-title":"Oncol. Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s13402-021-00614-z","article-title":"Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer","volume":"44","author":"Shimazaki","year":"2021","journal-title":"Cell Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature25167","article-title":"Senescence-associated reprogramming promotes cancer stemness","volume":"553","author":"Milanovic","year":"2018","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.cmet.2018.03.009","article-title":"Senescence Elicits Stemness: A Surprising Mechanism for Cancer Relapse","volume":"27","author":"Dou","year":"2018","journal-title":"Cell Metab."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Markl, B., Kazik, M., Harbeck, N., Jakubowicz, E., Hoffmann, R., Jung, T., Steinfeld, D., Schenkirsch, G., Schlimok, G., and Oruzio, D. (2019). Impact of uPA\/PAI-1 and disseminated cytokeratin-positive cells in breast cancer. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5857-0"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"42300","DOI":"10.18632\/oncotarget.15857","article-title":"Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K\/AKT and ERK signaling in esophageal squamous cell carcinoma","volume":"8","author":"Tian","year":"2017","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"23099","DOI":"10.18632\/oncotarget.15485","article-title":"The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis","volume":"8","author":"Brungs","year":"2017","journal-title":"Oncotarget"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.bbrc.2017.10.014","article-title":"PAI-1\/PIAS3\/Stat3\/miR-34a forms a positive feedback loop to promote EMT-mediated metastasis through Stat3 signaling in Non-small cell lung cancer","volume":"493","author":"Lin","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1158\/0008-5472.CAN-15-1796","article-title":"Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma","volume":"76","author":"Takayama","year":"2016","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9431","DOI":"10.1007\/s13277-015-3368-4","article-title":"Activated Pak4 expression correlates with poor prognosis in human gastric cancer patients","volume":"36","author":"Li","year":"2015","journal-title":"Tumour Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13046-015-0165-2","article-title":"Overexpression of P21-activated kinase 4 is associated with poor prognosis in non-small cell lung cancer and promotes migration and invasion","volume":"34","author":"Cai","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/j.1349-7006.2009.01252.x","article-title":"Identification of PAK4 as a putative target gene for amplification within 19q13.12-q13.2 in oral squamous-cell carcinoma","volume":"100","author":"Begum","year":"2009","journal-title":"Cancer Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"205.e13","DOI":"10.1016\/j.urolonc.2015.01.024","article-title":"p21-Activated kinase 4 predicts early recurrence and poor survival in patients with nonmetastatic clear cell renal cell carcinoma","volume":"33","author":"Liu","year":"2015","journal-title":"Urol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jss.2015.02.035","article-title":"P21-activated kinase 1 and 4 were associated with colorectal cancer metastasis and infiltration","volume":"196","author":"Song","year":"2015","journal-title":"J. Surg. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/apm.12705","article-title":"Prognostic value of p21-activated kinase 4 in resected pancreatic cancer","volume":"125","author":"Park","year":"2017","journal-title":"APMIS"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/18\/2945\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:50:42Z","timestamp":1760129442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/18\/2945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":45,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["diagnostics13182945"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics13182945","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]}}}